<DOC>
	<DOCNO>NCT02993107</DOCNO>
	<brief_summary>The purpose study demonstrate safety , tolerability , efficacy AR101 characterize oral desensitization immunotherapy ( CODIT ) peanut-allergic child adult complete ARC003 study .</brief_summary>
	<brief_title>PALISADE Follow-on Study ( ARC004 )</brief_title>
	<detailed_description>This international , multicenter , open-label , 2-arm follow-on study safety , tolerability , efficacy AR101 peanut-allergic individual complete ARC003 study . This study explore alternative dose regimen extend maintenance AR101 .</detailed_description>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Peanut Hypersensitivity</mesh_term>
	<criteria>Completion ARC003 study Written inform consent and/or assent subjects/guardians appropriate Use effective birth control sexually active female subject childbearing potential Early discontinuation ARC003 study Meets longitudinally applicable ARC003 study exclusion criterion ( Group 2 ) Failure tolerate â‰¥ 443 mg cumulative peanut protein mild symptom ARC003 study Exit DBPCFC Any condition , opinion Investigator , preclude participation reason safety</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>AR101</keyword>
	<keyword>Characterized Peanut Allergen</keyword>
	<keyword>CPNA ( Characterized Peanut Allergen )</keyword>
	<keyword>OIT ( oral immunotherapy )</keyword>
	<keyword>Peanut Allergy</keyword>
	<keyword>Allergy</keyword>
	<keyword>Peanut-Allergic Children</keyword>
	<keyword>Peanut-Allergic Adults</keyword>
	<keyword>Desensitization</keyword>
	<keyword>PALISADE</keyword>
</DOC>